Physician profile
Sidney P Smith
NPI 1104817410
$9,181.25
in general payments reported to CMS, 2019-2025
35 companies · $1,338 in 2025
The $1,338 reported for 2025 was more than what 80% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $740 · 2021: $1,415 · 2022: $1,389 · 2023: $1,070 · 2024: $2,352 · 2025: $1,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,862 · Travel and Lodging: $579 · Education: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,861.97 |
| Travel and Lodging | $579.12 |
| Education | $317.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,103.60 | 2019-2025 | Ilumya |
| Pfizer INC. | $1,053.55 | 2019-2025 | |
| Convatec INC. | $951.71 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $934.59 | 2019-2025 | Dupixent, Libtayo |
| Abbvie INC. | $894.91 | 2019-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $693.28 | 2020-2025 | |
| Incyte Corporation | $554.87 | 2021-2025 | Opzelura |
| Amgen INC. | $501.74 | 2019-2025 | Otezla, Otezla, Enbrel |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $397.66 | 2019-2024 | Siliq, Targretin, Duobrii |
| Ucb, INC. | $305.95 | 2019-2024 | Bimzelx |
| Janssen Biotech, INC. | $297.85 | 2020-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $276.90 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $236.87 | 2023-2025 | Sotyktu |
| Leo Pharma INC. | $224.12 | 2019-2025 | Adbry, Anzupgo |
| Genentech USA, INC. | $108.96 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $106.92 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Organogenesis INC. | $63.89 | 2022-2025 | Via Matrix, Puraply Wound Matrix |
| Galderma Laboratories, L.P. | $59.41 | 2024-2025 | Nemluvio |
| Stemline Therapeutics INC. | $57.11 | 2021 | |
| Dermavant Sciences, INC. | $51.64 | 2024 | Vtama |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.27 | 2019-2022 | |
| Celgene Corporation | $49.66 | 2019 | |
| Almirall LLC | $44.81 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | |
| Organon LLC | $23.02 | 2025 | Vtama |
| Aclaris Therapeutics, INC. | $21.97 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.29 | 2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $15.77 | 2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $14.93 | 2020 | |
| Boston Scientific Corporation | $13.70 | 2020 | |
| Dusa Pharmaceuticals, INC. | $12.64 | 2019 | |
| Mayne Pharma Commercial LLC | $7.49 | 2025 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.